Indeterminate Thyroid Nodule With High-Risk Ultrasound
A 47-year-old man has a 3.5 cm solid thyroid nodule with microcalcifications and irregular margins on ultrasound. Fine-needle aspiration yields two alcohol-fixed smears and one ThinPrep slide; one smear is air-dried and shows abundant colloid and sheets of follicular cells with mild crowding, rare nuclear grooves, and one possible pseudoinclusion. The aspirate is scantly cellular on the ThinPrep. The cytopathologist must sign out before the patient's surgery consult in 48 hours. The institution's molecular lab can run a 10-gene next-generation sequencing panel on residual material, but only if at least 20% tumor cellularity is present; the cell block has three small tissue fragments. The endocrinologist asks whether molecular testing can 'rule out cancer' and avoid surgery.
1. How should adequacy and the Bethesda category be assessed, and what category would you assign?
Read the worked answer
Adequacy is assessed on the overall sample, not on the ThinPrep alone. If the smears show abundant colloid and multiple groups of well-visualized follicular cells, the specimen can be adequate even when the liquid-based preparation is scanty. The cytologic features are not diagnostic of papillary carcinoma: mild crowding, rare grooves, and one possible pseudoinclusion are insufficient, especially without powdery chromatin, frequent pseudoinclusions, or psammoma bodies. The category depends on architecture and background. If the cells are arranged predominantly in sheets with abundant colloid, the findings fit atypia of undetermined significance/follicular lesion of undetermined significance rather than follicular neoplasm. If microfollicular architecture dominates, follicular neoplasm becomes more likely. Given the description, I would sign out as atypia of undetermined significance with a note that the nuclear features are focal and that ultrasound risk is high, rather than overcalling suspicious for malignancy.
2. What is the appropriate role of molecular testing in this case, and what limitations must be communicated?
Read the worked answer
Molecular testing can refine risk in indeterminate thyroid cytology, but it cannot rule out cancer. A negative panel lowers the probability of malignancy but does not eliminate it, particularly with a 3.5 cm solid nodule, microcalcifications, and irregular margins. The first practical question is specimen adequacy for the assay: three small cell-block fragments may not meet the 20% tumor cellularity threshold, and sending insufficient material wastes tissue and produces an uninformative result. If the material is adequate, use the result as an adjunct to ultrasound risk and clinical judgment, not as a veto against surgery. The endocrinologist should be told explicitly that a negative molecular result does not justify avoiding surgery in a high-risk ultrasound phenotype, and that a positive result increases concern but still requires histologic correlation.
3. What management recommendation would you give before the 48-hour surgery consult?
Read the worked answer
Recommend surgical consultation for diagnostic lobectomy or thyroidectomy rather than reassurance based on cytology alone. The nodule is large, solid, and has two high-risk ultrasound features; the cytology is indeterminate but not benign. If the category is atypia of undetermined significance, options include repeat aspiration, molecular testing if adequate, or diagnostic surgery, with the choice weighted by ultrasound risk and patient preference. Because the ultrasound is high risk, a negative molecular test would not safely avoid surgery. If the category is follicular neoplasm, surgery is generally required for histologic diagnosis. Communicate the uncertainty clearly: the cytopathologist cannot exclude malignancy, and the molecular test is a risk-stratification tool, not a rule-out test. Document the discussion and ensure the result is conveyed before the surgical consult.